三级片无码高清免费国产,中文字幕一区二区三区乱,国内精品久久久久久99蜜桃,亚洲一区电影网站在线观看

Stock(600222)Hot line:010-61006450

News

Understand the latest news of Leadingpharm

Leadingpharm and China Biology Signed an Agreement of Phase-I Clinical Research on a New Drug for Type 2 Diabetes

Release time:2021-07-28

Recently, Leadingpharm signed a cooperation agreement with China Biology on the phase I clinical research project of "insulin secreting peptide fusion protein injection". The project is developed by Lanzhou Institute of biological products of China Biology. Leadingpharm will be responsible for providing phase I clinical research services. The conclusion of this cooperation marks that Leadingpharm has officially joined the ranks of clinical CRO suppliers of China Biology and started the journey of strategic cooperation.
 

China Biology

China Biology was found in 1919 and is directly under the leadership of the National Health Commission. Now it is an important member enterprise of China Pharmaceutical Group, which is an enterprise of the world's top 500. It is a comprehensive biopharmaceutical enterprise in China with a long history, complete products and large scale, integrating scientific research, production, sales and postgraduate training. It has 12 secondary subsidiaries including Shanghai Institute of Biological Products, Lanzhou Institute of Biological Products and Wuhan Institute of Biological Products and 76 subsidiaries below secondary level, with 12551 employees. The company has a rich product line, covering six biological products fields: human vaccine, blood products, medical beauty, animal health care, antibody drugs and medical diagnosis. The annual output of 50 kinds of vaccines for human use can exceed 700 million doses, ranking sixth in the world, providing more than 80% of the vaccines for national immunization planning. Listed companies with an annual plasma collection volume of more than 1500 tons are producing 11 kinds of blood products. As the only botulinum toxin manufacturer certified and approved by the government in China, products are highly recognized by the market, providing the society with all-round and high-quality services for animal vaccines and related animal biological products. It has a complete antibody drug industry chain and a large molecular diagnosis industry chain with distinctive characteristics.
 

Leadingpharm

Leadingpharm (stock code: 600222) was established in 2005. It is a high-tech enterprise providing pharmacy pre-clinical research, clinical CRO and CDMO services to the whole world. It has been rated as "China’s Top 10 Pharmaceutical R&D Enterprises "for many years (ranked first in 2019). The company has nearly 1,000 R&D personnel, 80% of whom have a master's degree or above, all from well-known universities at home and abroad, specializing in medicinal chemistry, drug analysis and pharmaceutical preparations. The core R&D personnel have been engaged in the professional research work for many years, have rich experience in the development and production of new drugs, and have a thorough interpretation of registration regulations and guidelines. At present, more than 500 clinical studies have been completed, 50 to 100 BE studies and 10 to 20 clinical studies of Class I new drugs can be completed every year. Based on the rich experience in pharmaceutical R & D and clinical CRO of Leadingpharm and the CXO Integrated Service System Platform, it can meet the different needs of enterprises and provide good help for the transformation of innovative drugs.Based on Leadingpharm’s rich experience in pharmaceutical R & D and Clinical CRO and its CXO integrated service system platform, it can meet the different needs of enterprises and provide good help for the transformation of innovative drugs.
 

It is reported that "Insulin Secreting Peptide Fusion Protein Injection" is a GLP-1 receptor agonist. In vivo, it can promote insulin in islet B cells in a glucose concentration dependent manner by binding with GLP-1 receptor and activating the receptor, and reduce the secretion of glucagon in cells, so as to reduce blood glucose and have the effect of safe and effective control of blood samples. Compared with insulin, sulfonylurea and other routine drugs, the insulin secreting peptide fusion protein injection is expected to achieve good blood glucose control goal once every 10~15 days, and is more conducive to the treatment of patients with type 2 diabetes.

 

With the signing of the cooperation agreement between the two sides, the project will officially enter the phase I clinical research stage. The two sides will set up a project team to tackle tough problems and speed up the quality and efficiency of the project, and strive to promote early release of the fusion protein injection of insulin secreting peptide, which will bring more convenient treatment options for diabetics. Meanwhile, the two sides will continue to explore more levels of cooperation opportunities, access China's biological innovative drug platform with the CXO Whole Industry Chain Service System of Leadingpharm, inject new momentum into the R & D and transformation of innovative drugs, and jointly promote the development of China's pharmaceutical industry.
 

-END-

轉(zhuǎn)載聲明:未經(jīng)本網(wǎng)或本網(wǎng)權(quán)利人授權(quán),不得轉(zhuǎn)載、摘編或利用其他方式使用上述作品。已經(jīng)本網(wǎng)或本網(wǎng)權(quán)利人授權(quán)使用作品的,應(yīng)在授權(quán)范圍內(nèi)使用,并注明“來源:新領(lǐng)先醫(yī)藥科技”。

Recommend

一个妈妈的女儿bd在线观看| 国产精品线在线精品国语| 色婷婷综合久久久久久中文| 亚洲精品无码久久久久苍井空| 精品国产污污污网站免费看| 91在线手机精品超级观看| 免费在线看污的视频网站| 国产精品日韩av一区二区| 欧美图片久久一区二区三区| 欧美视频不卡一区二区三区| 国产亚av手机在线观看| 免费无码国产一级AV片| 久久精品国产亚洲一级二级| 99久久国产这里只有精品| 国产欧美一区二区精品久| 日韩精品无码人成中字幕| 人禽无码视频在线观看| 亚洲欧美在线图片50p| 情人在线观看| 午夜无码伦费影视在线观看| 成人污污污视频在线观看| 色婷婷中文字幕一区二区| 91欧美啪在线视频观看| 罗曼史在线观看| 黑人欧美色视频在线观看| 国产免费一区二区三区在线观看| 日本不卡一区二区在线播放| 性色av综合一区二区三区| 国产精品免费久久黄av片| 超麻豆精品传媒麻豆精品| 日本少妇的激情在线观看| 国产精品爱搞视频网网址| 噜噜噜视频在线免费观看| 国产欧美成人一区二区a片 | 天堂8在线天堂资源bt| 丁香婷婷激情五月在线观看| 亚洲一区二区三区四区操| 不卡一区二区三区四区欧美| 爱无码在线视频| 国产亚洲精品一区二区电影| 欧美性特黄在线视频网站|